How the Merck-Moderna mRNA Melanoma Vaccine Is Built per Patient
The therapy cut recurrence or death risk by 49% and distant metastasis or death risk by 59% in a 1,137-patient trial.
5 Articles
5 Articles
The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part
A late-stage trial found that a custom-built mRNA therapy added to immunotherapy reduced melanoma recurrence. An oncologist argues the result is a genuine milestone, but patients deserve clear answers on the size of the benefit, survival, cost, and access before the hype takes over.
After the announcement of positive results of the Moderna and Merck laboratories on a vaccine against melanoma, but also of the biotech Transgere for such treatment for head cancers, all hopes are allowed regarding the development of this new type of therapy in oncology.
Melanoma Breakthrough: mRNA Treatment Cuts Cancer Recurrence #shorts
An mRNA treatment dramatically cuts cancer's return by 49% and spread by 59%, building on Keytruda's success. Promising Phase 2 data fuels hope for lung, bladder, and kidney cancers. 🔗 Watch the full video: https://youtu.be/Z9BJb8lS1lo #CancerTreatment #MRNA #MedicalBreakthrough #Oncology
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
